EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

TIF1/TRIM24::FGFR1-rearranged myeloid/lymphoid neoplasm with eosinophilia and tyrosine kinase gene fusion presenting as mixed-phenotype acute leukemia: a case report

Rong Wei, Shasha Zhao, Yan Wei, Chengcheng Yan, Qian Jiang

Leukemia Research Reports · 2026 · 26 · 100613

DOI: 10.1016/j.lrr.2026.100613 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Leukemia Research Reports, 2026. Verfasst von Rong Wei und 4 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Ke…. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions are rare aggressive malignancies. FGFR1-rearranged cases are particularly high-risk. Among FGFR1 fusion partners, TIF1/TRIM24::FGFR1 is exceptionally rare. We report a 33-year-old woman presenting with fever, skin bruising, leukocytosis, thrombocytopenia, and circulating blasts. Bone marrow and flow cytometry identified abnormal B-lymphoblasts, myeloid blasts, and monocytic populations, supporting a mixed-phenotype acute leukemia presentation. Cytogenetics detected t(8;7)(p11;q34) translocation. Whole-transcriptome sequencing identified a TIF1/TRIM24::FGFR1 fusion transcript, confirmed by Sanger sequencing and FISH. RUNX1 missense mutation was also detected. The patient achieved complete remission after induction chemotherapy. However, after discontinuation of therapy and refusal of allo-HSCT, she relapsed rapidly with clonal evolution. A second remission was transient, and the patient died of cerebral hemorrhage. This case highlights the aggressive biology of TIF1/TRIM24::FGFR1-rearranged MLN-TK, the limitation of conventional chemotherapy, and the potential value of fusion-specific monitoring. Early allo-HSCT should be considered once remission is achieved, and FGFR1-directed therapy may represent a potential option in selected patients. However, clinical evidence remains limited and further studies are required.

Schlagwörter

Stichwörter der Autor:innen

8p11 myeloproliferative syndromeMLN-TKMixed-phenotype acute leukemiaRUNX1TIF1/TRIM24::FGFR

Autor:innen und Institutionen

  • Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, Chin…
  • Peking University People's Hospital, Qingdao, China.
  • Tianjin Kingmed Diagnostics Laboratory Co.Ltd, Tianjin, China.

Zitieren

APA

Wei, R., Zhao, S., Wei, Y., Yan, C., & Jiang, Q. (2026). TIF1/TRIM24::FGFR1-rearranged myeloid/lymphoid neoplasm with eosinophilia and tyrosine kinase gene fusion presenting as mixed-phenotype acute leukemia: a case report. Leukemia Research Reports, 26, 100613. https://doi.org/10.1016/j.lrr.2026.100613

Vancouver

Wei R, Zhao S, Wei Y, Yan C, Jiang Q. TIF1/TRIM24::FGFR1-rearranged myeloid/lymphoid neoplasm with eosinophilia and tyrosine kinase gene fusion presenting as mixed-phenotype acute leukemia: a case report. Leukemia Research Reports. 2026;26:100613. doi:10.1016/j.lrr.2026.100613

BibTeX
@article{Wei2026,
  author = {Wei, Rong and Zhao, Shasha and Wei, Yan and Yan, Chengcheng and Jiang, Qian},
  title = {TIF1/TRIM24::FGFR1-rearranged myeloid/lymphoid neoplasm with eosinophilia and tyrosine kinase gene fusion presenting as mixed-phenotype acute leukemia: a case report},
  journal = {Leukemia Research Reports},
  year = {2026},
  volume = {26},
  pages = {100613},
  doi = {10.1016/j.lrr.2026.100613}
}
Kostenlos starten →